199 related articles for article (PubMed ID: 24562632)
1. Multitargeted antiangiogenic tyrosine kinase inhibitors combined to chemotherapy in metastatic breast cancer: a systematic review and meta-analysis.
Wang Z; Wang M; Yang F; Nie W; Chen F; Xu J; Guan X
Eur J Clin Pharmacol; 2014 May; 70(5):531-8. PubMed ID: 24562632
[TBL] [Abstract][Full Text] [Related]
2. Chemotherapy plus multitargeted antiangiogenic tyrosine kinase inhibitors or chemotherapy alone in advanced NSCLC: a meta-analysis of randomized controlled trials.
Xiao YY; Zhan P; Yuan DM; Liu HB; Lv TF; Song Y; Shi Y
Eur J Clin Pharmacol; 2013 Feb; 69(2):151-9. PubMed ID: 22729611
[TBL] [Abstract][Full Text] [Related]
3. Sunitinib alone or in combination with chemotherapy for the treatment of advanced breast cancer: A systematic review and meta-analysis.
Elgebaly A; Menshawy A; El Ashal G; Osama O; Ghanem E; Omar A; Negida A
Breast Dis; 2016 Jul; 36(2-3):91-101. PubMed ID: 27612040
[TBL] [Abstract][Full Text] [Related]
4. Vascular-endothelial-growth-factor (VEGF) targeting therapies for endocrine refractory or resistant metastatic breast cancer.
Wagner AD; Thomssen C; Haerting J; Unverzagt S
Cochrane Database Syst Rev; 2012 Jul; (7):CD008941. PubMed ID: 22786517
[TBL] [Abstract][Full Text] [Related]
5. Association of Cyclin-Dependent Kinases 4 and 6 Inhibitors With Survival in Patients With Hormone Receptor-Positive Metastatic Breast Cancer: A Systematic Review and Meta-analysis.
Li J; Huo X; Zhao F; Ren D; Ahmad R; Yuan X; Du F; Zhao J
JAMA Netw Open; 2020 Oct; 3(10):e2020312. PubMed ID: 33048129
[TBL] [Abstract][Full Text] [Related]
6. Efficacy and safety of chemotherapy or tyrosine kinase inhibitors combined with bevacizumab versus chemotherapy or tyrosine kinase inhibitors alone in the treatment of non-small cell lung cancer: a systematic review and meta-analysis.
Sun L; Ma JT; Zhang SL; Zou HW; Han CB
Med Oncol; 2015 Feb; 32(2):473. PubMed ID: 25603953
[TBL] [Abstract][Full Text] [Related]
7. Multi-targeted antiangiogenic tyrosine kinase inhibitors in advanced non-small cell lung cancer: meta-analyses of 20 randomized controlled trials and subgroup analyses.
Liang W; Wu X; Hong S; Zhang Y; Kang S; Fang W; Qin T; Huang Y; Zhao H; Zhang L
PLoS One; 2014; 9(10):e109757. PubMed ID: 25329056
[TBL] [Abstract][Full Text] [Related]
8. The addition of anti-angiogenic tyrosine kinase inhibitors to chemotherapy for patients with advanced non-small-cell lung cancers: A meta-analysis of randomized trials.
Li BT; Barnes TA; Chan DL; Naidoo J; Lee A; Khasraw M; Marx GM; Kris MG; Clarke SJ; Drilon A; Rudin CM; Pavlakis N
Lung Cancer; 2016 Dec; 102():21-27. PubMed ID: 27987583
[TBL] [Abstract][Full Text] [Related]
9. Effectiveness of targeted therapy in patients with previously untreated metastatic breast cancer: a systematic review and meta-analysis.
Kawalec P; Łopuch S; Mikrut A
Clin Breast Cancer; 2015 Apr; 15(2):90-100.e1. PubMed ID: 25441421
[TBL] [Abstract][Full Text] [Related]
10. Cyclin-dependent kinase 4 and 6 inhibitors in hormone receptor-positive, human epidermal growth factor receptor-2 negative advanced breast cancer: a meta-analysis of randomized clinical trials.
Li J; Fu F; Yu L; Huang M; Lin Y; Mei Q; Lv J; Wang C
Breast Cancer Res Treat; 2020 Feb; 180(1):21-32. PubMed ID: 31970560
[TBL] [Abstract][Full Text] [Related]
11. Bevacizumab in metastatic breast cancer: a meta-analysis of randomized controlled trials.
Valachis A; Polyzos NP; Patsopoulos NA; Georgoulias V; Mavroudis D; Mauri D
Breast Cancer Res Treat; 2010 Jul; 122(1):1-7. PubMed ID: 20063120
[TBL] [Abstract][Full Text] [Related]
12. Overall survival and progression-free survival with cyclin-dependent kinase 4/6 inhibitors plus endocrine therapy in breast cancer: an updated meta-analysis of randomized controlled trials.
Tian Q; Gao H; Zhou Y; Yang J
Eur Rev Med Pharmacol Sci; 2021 Dec; 25(23):7252-7267. PubMed ID: 34919224
[TBL] [Abstract][Full Text] [Related]
13. Systematic review of lapatinib in combination with letrozole compared with other first-line treatments for hormone receptor positive(HR+) and HER2+ advanced or metastatic breast cancer(MBC).
Riemsma R; Forbes CA; Amonkar MM; Lykopoulos K; Diaz JR; Kleijnen J; Rea DW
Curr Med Res Opin; 2012 Aug; 28(8):1263-79. PubMed ID: 22738819
[TBL] [Abstract][Full Text] [Related]
14. The efficacy and safety of panitumumab in the treatment of patients with metastatic colorectal cancer: a meta-analysis from five randomized controlled trials.
Liang RF; Zheng LL
Drug Des Devel Ther; 2015; 9():4471-8. PubMed ID: 26300630
[TBL] [Abstract][Full Text] [Related]
15. Safety and efficacy of addition of VEGFR and EGFR-family oral small-molecule tyrosine kinase inhibitors to cytotoxic chemotherapy in solid cancers: a systematic review and meta-analysis of randomized controlled trials.
Funakoshi T; Latif A; Galsky MD
Cancer Treat Rev; 2014 Jun; 40(5):636-47. PubMed ID: 24629273
[TBL] [Abstract][Full Text] [Related]
16. CDK4/6 inhibitor treatment for patients with hormone receptor-positive, HER2-negative, advanced or metastatic breast cancer: a US Food and Drug Administration pooled analysis.
Gao JJ; Cheng J; Bloomquist E; Sanchez J; Wedam SB; Singh H; Amiri-Kordestani L; Ibrahim A; Sridhara R; Goldberg KB; Theoret MR; Kluetz PG; Blumenthal GM; Pazdur R; Beaver JA; Prowell TM
Lancet Oncol; 2020 Feb; 21(2):250-260. PubMed ID: 31859246
[TBL] [Abstract][Full Text] [Related]
17. Antiangiogenesis therapy in ovarian cancer patients: An updated meta-analysis for 15 randomized controlled trials.
Jiang Y; Sun X; Kong B; Jiang J
Medicine (Baltimore); 2018 Aug; 97(34):e11920. PubMed ID: 30142803
[TBL] [Abstract][Full Text] [Related]
18. Risks and benefits of bevacizumab combined with chemotherapy for advanced or metastatic breast cancer: a meta-analysis of randomized controlled trials.
Miyashita M; Hattori M; Takano T; Toyama T; Iwata H
Breast Cancer; 2020 May; 27(3):347-354. PubMed ID: 31974704
[TBL] [Abstract][Full Text] [Related]
19. Bevacizumab in combination with first-line chemotherapy in patients with metastatic colorectal cancer: a meta-analysis.
Hu W; Xu WS; Liao XF; He HJ
Minerva Chir; 2015 Dec; 70(6):451-8. PubMed ID: 26013763
[TBL] [Abstract][Full Text] [Related]
20. The efficacy and safety of bevacizumab combined with chemotherapy in treatment of HER2-negative metastatic breast cancer: a meta-analysis based on published phase III trials.
Fang Y; Qu X; Cheng B; Chen Y; Wang Z; Chen F; Xiong B
Tumour Biol; 2015 Mar; 36(3):1933-41. PubMed ID: 25387808
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
